Craft

Compugen

Stock Price

₪6.2

2024-10-29

Market Capitalization

₪57.5 B

2024-10-29

Revenue

$72.8 M

FY, 2025

Compugen Summary

Company Summary

Overview
Compugen is a drug and diagnostic discovery company providing novel product candidates addressing important unmet therapeutic and diagnostic needs to pharmaceutical, biotech and diagnostic companies under milestone and royalty bearing, or other revenue sharing agreements. Compugen's discovery efforts consist of in silico (by computer) hypothesis-driven product candidate prediction and selection followed by in vitro and in vivo experimental validation. Compugen's unique in silico prediction and selection capabilities are based on a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology tools.
Type
Public
Status
Active
Founded
1993
HQ
Holon, IL | view all locations
Website
https://www.cgen.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Anat Cohen-Dayag

    Anat Cohen-Dayag, President and CEO, Director

    • Paul Sekhri, Chairman of the Board

      • Ari Krashin

        Ari Krashin, Chief Financial and Operating Officer

        • Henry Adewoye

          Henry Adewoye, Senior Vice President and Chief Medical Officer

          LocationsView all

          2 locations detected

          • Holon, Center District HQ

            Israel

            26 Harokmim St

          • South San Francisco, CA

            United States

            395 Oyster Point Blvd #307

          Compugen Financials

          Summary Financials

          Revenue (FY, 2025)
          $72.8M
          Gross profit (FY, 2025)
          $63.5M
          Net income (FY, 2025)
          $35.3M
          Cash (FY, 2025)
          $90.6M
          EBIT (FY, 2025)
          $31.3M

          Footer menu